Search clinical trials for: PD 0332991

Total 1169 results

Gustave Roussy, Cancer Campus, Grand Paris

Completed

Randomized Phase II Study to Assess PD 0332991 in Breast Cancer (POP)

Untreated Operable Early Breast Cancer

France
University of Florida

Completed

Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.

Non-small Cell Lung Cancer

United States
The Affiliated Hospital of Qingdao University

Not yet recruiting

PD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung Cancer

Efficacy | Safety
Peking Union Medical College

Recruiting

Neoadjuvant Immunotherapy With Chemotherapy for Stage I-IIIB Non-Small Cell Lung Cancer Patients

Non-small Cell Lung Cancer

China
Maatschap Cardiologie Zwolle
Abbott; Radboudumc Technology Center; Clinical Studies

Recruiting

Use of Physiology to Evaluate Procedural Result After PCI CTO (ULTRA-CTO)

Percutaneous Coronary Revascularisation | Complex Coronary Lesion

Netherlands
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI); Incyte Corporation

Recruiting

INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer

Pancreatic Cancer Metastatic | Pancreatic Cancer Non-resectable

United States
China Medical University, China

Recruiting

PD-1 Antibody + XELOX in 1st Line Serum A-fetoprotein (AFP)-Elevated Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric or Gastroesophageal Junction Adenocarcinoma | AFP

China
Centre Hospitalier Universitaire Vaudois

Active, not recruiting

Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)

Metastatic Melanoma Naive to Immune Therapy in Metastatic Setting

Switzerland
Chongqing University Cancer Hospital

Recruiting

The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC

Head and Neck Squamous Cell Carcinoma

China
Scholar Rock, Inc.

Active, not recruiting

SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)

Cancer

United States, Korea, Republic of
Zhejiang University

Terminated

Perioperative Therapy for Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Guangzhou University of Traditional Chinese Medicine

Unknown

PD-1 Monoclonal Antibody in Pre-treated Lymphoepithelioma-like Carcinoma

Lymphoepithelioma-Like Carcinoma

China
Fudan University

Active, not recruiting

Multiple Target Kinase Inhibitor and Anti-Programmed Death-1 Antibody in Patients With Advanced Thyroid Cancer

Thyroid Cancer

China
Pengyuan Liu
Zhejiang Hospital

Completed

Hyperthermia Combined With Immune Checkpoint Inhibitor Therapy for Advanced Gastrointestinal Tumours (HEAIS001)

Gastrointestinal Tumor

China
Emory University
National Cancer Institute (NCI); Pfizer; National Institutes of Health (NIH)

Completed

Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (ASPIRE)

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Metastatic Breast Carcinoma

United States
Wuhan Union Hospital, China

Recruiting

Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction

Gastroesophageal Junction Cancer | PD-1 | Neoadjuvant Chemoradiotherapy

China
Fudan University

Recruiting

Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence (IMPROVE)

Colorectal Cancer | Liver Metastases | Radiotherapy | Immunotherapy

China
Richard D. Carvajal

Completed

Epacadostat and Pembrolizumab in Patients With GIST

Gastrointestinal Stromal Tumors

United States
Sir Run Run Shaw Hospital
Hangzhou Neoantigen Therapeutics Co., Ltd.

Recruiting

Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors

Advanced Malignant Solid Tumor

China
Ze-yang Ding, MD
Geneplus-Beijing Co. Ltd.; Chinese Cooperative Group of Liver Cancer (CCGLC)

Recruiting

DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma (CCGLC-009)

Cholangiocarcinoma Non-resectable

China
The Second Affiliated Hospital of Chongqing Medical...
Guizhou Provincial People's Hospital; The Affiliated Hospital Of Southwest...

Not yet recruiting

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)

Chronic Hepatitis b | Anti-PD-1 Antibody

China
Fudan University

Not yet recruiting

PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery

Gastric Cancer | MSI-H | Adjuvant Therapy | PD-1 Immunotherapy

China
Blokhin's Russian Cancer Research Center

Recruiting

Evaluation of Cytokine Biomarkers in Melanoma Patients During Immunotherapy

Melanoma

Russian Federation
Sun Yat-sen University

Recruiting

Transarterial Infusion of PD-1 Antibody Plus TACE-HAIC for Unresectable HCC: a Single-arm, Phase 2 Clinical Trial (AIPD-1)

Hepatocellular Carcinoma

China
China Medical University, China

Recruiting

Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.

Metastatic Colorectal Adenocarcinoma | MSS | pMMR

China
Cancer Hospital of Guangxi Medical University

Unknown

A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection

Hepatocellular Carcinoma

China
Xiangya Hospital of Central South University
Wu Jieping Medical Foundation

Recruiting

Radiotherapy Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of NSCLC Patients With Symptomatic Brain Metastases

Non-small Cell Lung Cancer Metastatic | Brain Metastases

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma

Perihilar Cholangiocarcinoma

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

A Perspective, Self-control Study on the Progression of Carotid Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up

Carotid Artery Plaque | Plaque, Atherosclerotic | Immune Checkpoint Inhibitors | Programmed Cell Death Protein 1 Inhibitor | Intimal Medial Thickness of Internal Carotid Artery

China
The First Hospital of Jilin University

Not yet recruiting

CT and MRI in Prediction of Response in Patients With Gastric Cancer Following Neoadjuvant Chemotherapy and/or Immunotherapy

Gastric Cancer | Magnetic Resonance Imaging | Neoadjuvant Chemotherapy | Neoadjuvant Immunotherapy | Tomography, X-Ray Computed
Ruijin Hospital

Not yet recruiting

PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT

Lymphoma, Large B-Cell, Diffuse | Chemotherapy | Transplantation

China
Shanghai Zhongshan Hospital

Recruiting

PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment

Cholangiocarcinoma, Intrahepatic | PD-L1 | CTLA4

China
Fujian Cancer Hospital

Not yet recruiting

Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy

NSCLC Stage IV

China
Shanghai Zhongshan Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Neoadjuvant Chemoradiation Plus PD-1 Antibody(SHR-1210) in Locally Advanced Proximal Stomach Adenocarcinoma (Neo-PLANET)

Gastric Adenocarcinoma

China
Johnson & Johnson Healthcare Products Division...

Completed

Safety Study for an All-in-One Body and Personal Lubricant

Lubricating Agents

United States
Ningbo Cancer Hospital

Unknown

PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies

Advanced Cancer | Solid Tumor, Adult

China
GlaxoSmithKline

Completed

A Long Term Follow-up Study up to 4 Years After Study Vaccination to Assess Immunogenicity and Safety of the Investigational Vaccine in Adults

Respiratory Disorders

Belgium
Chinese PLA General Hospital

Unknown

An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer

Pancreatic Cancer

China
LigaChem Biosciences, Inc.
AntibodyChem Biosciences, Inc.

Recruiting

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Advanced Solid Tumors

United States, Canada
First Affiliated Hospital of Guangxi Medical University

Recruiting

Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer

Cervical Cancer

China
Third Affiliated Hospital, Sun Yat-Sen University

Recruiting

Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer

Colorectal Cancer | Neoadjuvant Therapy | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)

China
Shanghai Zhongshan Hospital
Zhejiang Cancer Hospital; Sun Yat-sen University; Cancer Institute and Hospital... and other collaborators

Recruiting

Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC (iCROSS)

Esophageal Squamous Cell Carcinoma Stage II | Esophageal Squamous Cell Carcinoma Stage III

China
Sun Yat-sen University

Recruiting

Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma

Neoadjuvant Therapy | Apatinib | Carilizumab | Recurrent High-Grade Glioma

China
LaNova Medicines Limited

Terminated

Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumours

Advanced Solid Tumor

United States
Taizhou Hanzhong biomedical co. LTD

Active, not recruiting

Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors

Advanced Solid Tumor

China
Christoph Aufricht

Terminated

Safety and Efficacy of the Addition of Alanyl-Glutamine-Dipeptide to Dialysis Solution in Peritoneal Dialysis

End Stage Renal Disease

Austria
Sun Yat-sen University
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

PD-1 Blockade Combined With De-intensification Radical Chemoradiotherapy in Nasopharyngeal Carcinoma (DIAMOND)

Nasopharyngeal Carcinoma

China
Grupo Español de Investigación en Neurooncología
Pfizer

Completed

Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved

Oligoastrocytoma | Oligodendroglioma

Spain
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Immunotherapy in Upper Tract Urothelial Carcinoma (VESUVIO)

Urothelial Carcinoma
Shanghai Chest Hospital

Not yet recruiting

Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE) (RICE)

Chemotherapy | Immunotherapy | Concurrent Chemoradiotherapy | Esophageal Squamous Cell Carcinomas

Search clinical trials for: PD 0332991

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations